ESRRA and cancer: Considering that cancer cells are more sensitive to rapid increases of ROS levels than normal cells [40], our study provides a plausible mechanistic explanation for that targeted inhibition of ERRα to suppress the progression of TNBC via a ROS-dependent manner, which will selectively kill cancer cells without causing significant toxicity to normal cells [41].